Critical appraisal of clinical studies and meta-analyses - An educational article on the most important validity criteria according to Evidence-based Medicine (EbM)

被引:0
作者
Czekalla, Joerg [1 ]
机构
[1] Janssen Cilag GmbH, Therapeut Area CNS, Med & Sci Affairs, D-41470 Neuss, Germany
来源
PSYCHOPHARMAKOTHERAPIE | 2006年 / 13卷 / 06期
关键词
psychiatry; evidence-based medicine; clinical studies; critical appraisal; meta-analysis; clinical benefit assessment; absolute risk reduction (ARR); number needed to treat (NNT);
D O I
暂无
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The Oxford Dictionary of Current English defines ,,evidence" as,available facts, circumstances, etc. indicating whether a thing is true or not true." In conjunction with clinical expertise, which can just be acquired by clinical practice, evidence-based medicine (EbM) is considered as a lifelong learning process which is targeted on adjustment on fast varying medical knowledge by continuous problem-focused learning. Thus, there is an increasing need for medical education due to the systematic assessment of clinical studies by mental health care specialists. The associated methodology has been developed in the eighties by the Cochrane Collaboration in Oxford, whose intention is to compile systematic reviews regarding assessment of therapies as well as to update and publish them. The critical appraisal of clinical studies and meta-analyses is based on validity criteria with regard to study design, biostatistics, study population and interpretation according to Sackett et al., and will be summarized. According to the methods of evidence-based medicine the estimation of clinical benefit by calculation of absolute risk reduction (ARR) und number needed to treat (NNT) will be described with a focus on psychiatric studies and examples. Meanwhile efforts are made by psychiatrists to make decisions on best evidence available at present in combination with clinical expertise.
引用
收藏
页码:224 / +
页数:12
相关论文
共 7 条
  • [1] Primary prevention of acute coronary events with lovastatin in men and women with average cholesterol levels - Results of AFCAPS/TexCAPS
    Downs, JR
    Clearfield, M
    Weis, S
    Whitney, E
    Shapiro, DR
    Beere, PA
    Langendorfer, A
    Stein, EA
    Kruyer, W
    Gotto, AM
    [J]. JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION, 1998, 279 (20): : 1615 - 1622
  • [2] GREENBERG G, 1985, BMJ-BRIT MED J, V291, P97
  • [3] Once-daily atomoxetine treatment for children and adolescents with attention deficit hyperactivity disorder: A randomized, placebo-controlled study
    Michelson, D
    Allen, AJ
    Busner, J
    Casat, C
    Dunn, D
    Kratochvil, C
    Newcorn, J
    Sallee, FR
    Sangal, RB
    Saylor, K
    West, S
    Kelsey, D
    Wernicke, J
    Trapp, NJ
    Harder, D
    [J]. AMERICAN JOURNAL OF PSYCHIATRY, 2002, 159 (11) : 1896 - 1901
  • [4] Atomoxetine in the treatment of children and adolescents with attention-deficit/hyperactivity disorder: A randomized, placebo-controlled, dose-response study
    Michelson, D
    Faries, D
    Wernicke, J
    Kelsey, D
    Kendrick, K
    Sallee, FR
    Spencer, T
    [J]. PEDIATRICS, 2001, 108 (05) : E83
  • [5] Improving the quality of reports of meta-analyses of randomised controlled trials: the QUOROM statement
    Moher, D
    Cook, DJ
    Eastwood, S
    Olkin, I
    Rennie, D
    Stroup, DF
    [J]. LANCET, 1999, 354 (9193) : 1896 - 1900
  • [6] Sackett D.L., 1997, Evidence-Based Medicine: How to Practice and Teach EBM
  • [7] THOMPSON SG, 1995, SYSTEMATIC REV, P64